Detalhe da pesquisa
1.
First-in-human trial of the PI3Kß-selective inhibitor SAR260301 in patients with advanced solid tumors.
Cancer
; 124(2): 315-324, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-28976556
2.
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.
Eur J Cancer
; 87: 131-139, 2017 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29145039
3.
Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.
Oncotarget
; 8(45): 79546-79555, 2017 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29108334